CXCR4
X4 Pharmaceuticals Launches Phase Ib Trial for Mavorixafor in Rare Non-Hodgkin's Lymphoma
The trial will enroll patients with CXCR4-mutated Waldenström’s macroglobulinemia and study the safety and tolerability of mavorixafor and ibrutinib.
The trial will enroll patients with CXCR4-mutated Waldenström’s macroglobulinemia and study the safety and tolerability of mavorixafor and ibrutinib.